LPMX 4/5
Alternative Names: LPMX-4/5; Multidrug liposomeLatest Information Update: 28 Sep 2020
Price :
$50 *
At a glance
- Originator Hebrew University of Jerusalem
- Developer Lipomedix Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for preclinical development in Solid-tumours in Israel (Parenteral)